A detailed history of Janus Henderson Group PLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 249,440 shares of ALNY stock, worth $68.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
249,440
Previous 178,954 39.39%
Holding current value
$68.3 Million
Previous $26.7 Million 126.64%
% of portfolio
0.03%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $10.1 Million - $17.4 Million
70,486 Added 39.39%
249,440 $60.6 Million
Q1 2024

May 15, 2024

SELL
$146.51 - $198.2 $14.5 Million - $19.6 Million
-99,127 Reduced 35.65%
178,954 $26.7 Million
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $2.33 Million - $3.03 Million
-15,409 Reduced 5.25%
278,081 $53.2 Million
Q3 2023

Nov 14, 2023

BUY
$170.77 - $211.65 $281,941 - $349,434
1,651 Added 0.57%
293,490 $52 Million
Q2 2023

Aug 14, 2023

SELL
$185.01 - $212.05 $1.3 Million - $1.49 Million
-7,004 Reduced 2.34%
291,839 $55.4 Million
Q1 2023

May 15, 2023

SELL
$182.66 - $235.53 $30.4 Million - $39.2 Million
-166,545 Reduced 35.79%
298,843 $59.9 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $20.2 Million - $26.3 Million
-109,116 Reduced 18.99%
465,388 $111 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $17.3 Million - $29 Million
124,791 Added 27.75%
574,504 $115 Million
Q2 2022

Aug 15, 2022

SELL
$120.42 - $169.29 $17.9 Million - $25.2 Million
-148,735 Reduced 24.85%
449,713 $65.6 Million
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $12.4 Million - $16.9 Million
97,115 Added 19.37%
598,448 $97.7 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $76.5 Million - $100 Million
479,756 Added 2223.46%
501,333 $85 Million
Q3 2021

Nov 16, 2021

BUY
$169.75 - $207.73 $1.67 Million - $2.05 Million
9,852 Added 84.03%
21,577 $4.08 Million
Q2 2021

Aug 16, 2021

SELL
$128.63 - $176.89 $830,692 - $1.14 Million
-6,458 Reduced 35.52%
11,725 $1.99 Million
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $9.14 Million - $12.7 Million
-72,072 Reduced 79.85%
18,183 $2.57 Million
Q4 2020

Feb 16, 2021

SELL
$122.97 - $147.0 $8.89 Million - $10.6 Million
-72,314 Reduced 44.48%
90,255 $11.7 Million
Q3 2020

Nov 16, 2020

SELL
$121.19 - $165.49 $7.4 Million - $10.1 Million
-61,092 Reduced 27.31%
162,569 $23.7 Million
Q2 2020

Aug 14, 2020

SELL
$104.21 - $156.44 $19.2 Million - $28.8 Million
-183,796 Reduced 45.11%
223,661 $33.1 Million
Q1 2020

May 14, 2020

BUY
$93.12 - $133.99 $33 Million - $47.4 Million
353,980 Added 661.93%
407,457 $44.4 Million
Q4 2019

Feb 18, 2020

BUY
$74.51 - $124.23 $964,010 - $1.61 Million
12,938 Added 31.91%
53,477 $6.16 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $977,569 - $1.21 Million
13,788 Added 51.54%
40,539 $3.26 Million
Q2 2019

Jul 31, 2019

BUY
$65.86 - $92.79 $99,316 - $139,927
1,508 Added 5.97%
26,751 $1.94 Million
Q1 2019

Apr 30, 2019

BUY
$72.76 - $93.45 $61,191 - $78,591
841 Added 3.45%
25,243 $2.36 Million
Q4 2018

Feb 06, 2019

SELL
$62.67 - $88.33 $75,204 - $105,996
-1,200 Reduced 4.69%
24,402 $1.78 Million
Q3 2018

Nov 09, 2018

SELL
$87.52 - $122.67 $6.73 Million - $9.43 Million
-76,900 Reduced 75.02%
25,602 $2.24 Million
Q2 2018

Aug 10, 2018

SELL
$88.31 - $107.8 $35.5 Million - $43.3 Million
-401,809 Reduced 79.67%
102,502 $10.1 Million
Q1 2018

May 14, 2018

BUY
$115.92 - $148.54 $1.24 Million - $1.59 Million
10,692 Added 2.17%
504,311 $60.1 Million
Q4 2017

Feb 09, 2018

SELL
$114.49 - $139.98 $21.7 Million - $26.5 Million
-189,401 Reduced 27.73%
493,619 $62.7 Million
Q3 2017

Nov 14, 2017

BUY
$72.53 - $118.27 $1.14 Million - $1.86 Million
15,687 Added 2.35%
683,020 $0
Q2 2017

Aug 17, 2017

BUY
N/A
667,333
667,333 $53.2 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $33.7B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.